Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.01.2023 | Case report

Inotuzumab-ozogamicin

Lack of efficacy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Rubinstein J, et al. THE CHOICE OF CONVENTIONAL CHEMOTHERAPY OR IMMUNOTHERAPY AS BRIDGING THERAPY DOES NOT APPEAR TO IMPACT CLINICAL RESPONSE TO CD19 DIRECTED CAR-T THERAPY IN PEDIATRIC B-ALL. Pediatric Blood and Cancer 69 (Suppl. 5): S179 abstr. EP066, Nov 2022. Available from: URL: http://doi.org/10.1002/pbc.29952 [abstract] Rubinstein J, et al. THE CHOICE OF CONVENTIONAL CHEMOTHERAPY OR IMMUNOTHERAPY AS BRIDGING THERAPY DOES NOT APPEAR TO IMPACT CLINICAL RESPONSE TO CD19 DIRECTED CAR-T THERAPY IN PEDIATRIC B-ALL. Pediatric Blood and Cancer 69 (Suppl. 5): S179 abstr. EP066, Nov 2022. Available from: URL: http://​doi.​org/​10.​1002/​pbc.​29952 [abstract]
Metadaten
Titel
Inotuzumab-ozogamicin
Lack of efficacy: case report
Publikationsdatum
01.01.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-30887-2

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Antineoplastics

Case report

Antineoplastics

Case report

Hyaluronic-acid

Case report

Etoposide

Case report

Multiple drugs